You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 2
  • P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

Article info

Article menu

Download PDFPDF

E-Poster Presentations
P06 Cell Therapy in Solid Tumors
P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells
Free

Authors

  • MI Strecker 1Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • F Strassheimer 1Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • J Reul 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany 4Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen, Germany PubMed articlesGoogle scholar articles
  • PN Harter 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany 5Institute of Neurology (Edinger Institute), Goethe University Hospital, Frankfurt, Germany PubMed articlesGoogle scholar articles
  • T Tonn 6Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany PubMed articlesGoogle scholar articles
  • JP Steinbach 1Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • WS Wels 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany 7Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany PubMed articlesGoogle scholar articles
  • CJ Buchholz 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany 4Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen, Germany PubMed articlesGoogle scholar articles
  • MC Burger 1Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany 2Frankfurt Cancer Institute (FCI), Frankfurt, Germany 3German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles

Citation

Strecker M, Strassheimer F, Reul J, et al
P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-ITOC7.92

Publication history

  • First published October 1, 2020.
Online issue publication 
October 01, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.